Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

3

Revenue 2017

MabThera/Rituxan

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. MabThera/Rituxan was produced by Roche.

Roche and AbbVie prepare to move Venclexta into first-line CLL

Roche and AbbVie prepare to move Venclexta into first-line CLL Gazyva is a follow-up to Roche’s big-selling Rituxan/MabThera (rituximab) anti-CD20 drug – a mainstay of CLL therapy given alongside chemotherapy – and was approved alongside chlorambucil for ... Venclexta is a key growth product for both companies

Roche’s new flu pill Xofluza approved in US

Roche’s new flu pill Xofluza approved in US Roche is in need of a new set of innovative products, as its older generation of blockbusters, Avastin, Herceptin and MabThera/Rituxan come under competition from biosimilars.

Celgene to launch five new products through to 2020

Celgene to launch five new products through to 2020 Also on the agenda is a closer look at the AUGMENT trial of Revlimid with Roche’s Rituxan (rituximab) in relapsed/refractory indolent lymphoma.

Ocrevus surge keeps Roche smiling in Q3

Ocrevus surge keeps Roche smiling in Q3 As expected, biosimilar competition to two of its top products – MabThera and Herceptin – weighed heavy on Roche in the third quarter in Europe. ... 9% overall thanks to gains in the US, where it is sold as Rituxan, as well as international markets,

Encouraging data for Roche flu drug ahead of FDA decision

Encouraging data for Roche flu drug ahead of FDA decision Roche is in need of a new set of innovative products, as its older generation of blockbusters, Avastin, Herceptin and MabThera/Rituxan come under competition from biosimilars.

[ Previous 5 results ] 2 3 4 5 6 7 8 9 10 11 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

DEMAND DIVERSITY REPORT 01: Exploring attitudes towards clinical research among people from different ethnic groups in the UK
This report reveals insights from the people themselves, and discusses the starting points for overcoming current challenges....
Why are new medicinal products denied reimbursement in France?
Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative...
OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa
Ben Speller shares his thoughts on the value of disease specific congresses...

Infographics